Ferrarese C, Sala G, Riva R, Begni B, Zoia C, Tremolizzo L, Galimberti G, Millul A, Bastone A, Mennini T, Balzarini C, Frattola L, Beghi E
Department of Neurosciences and Biomedical Technologies, University of Milano-Bicocca, Ospedale San Gerardo, Monza, Italy.
Neurology. 2001 Jan 23;56(2):270-2. doi: 10.1212/wnl.56.2.270.
Decreased glutamate uptake and a loss of the astrocytic glutamate transporter EAAT2 (GLT-1) have been shown in spinal cord and motor cortex of patients with ALS. Because platelets express the three major glutamate transporter subtypes, including GLT-1, and possess a high-affinity glutamate uptake, the authors investigated glutamate uptake in platelets from patients with ALS and controls. A 43% reduction of high-affinity glutamate uptake rate (p < 0.0001) was observed in patients with ALS compared with normal controls and chronic neurologic disorder patients, suggesting a systemic impairment of glutamate uptake in ALS.
在肌萎缩侧索硬化症（ALS）患者的脊髓和运动皮层中，已发现谷氨酸摄取减少以及星形胶质细胞谷氨酸转运体EAAT2（GLT-1）缺失。由于血小板表达包括GLT-1在内的三种主要谷氨酸转运体亚型，且具有高亲和力的谷氨酸摄取能力，因此作者研究了ALS患者和对照组血小板中的谷氨酸摄取情况。与正常对照组和慢性神经系统疾病患者相比，ALS患者的高亲和力谷氨酸摄取率降低了43%（p < 0.0001），这表明ALS患者存在全身性谷氨酸摄取障碍。
